Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Claud B who wrote (6472)	5/5/1999 11:54:00 PM
From: Tokyo VD	Read Replies (2) \| Respond to of 7041

Claud, You are correct. SGP did make a presentation that featured limited data from one trial with approximately 450 men. This is the same presentation SGP has made in other cities around the world over the past six months. Why does SGP want to emphasize this trial versus disclosing outcomes from all studies? Why did SGP only disclose limited endpoint data (the change in the baseline IIEF score) and not other trial (penetration rates)? Only SGP knows the answers to these questions. What we do know is that SGP is like the rest of us: We tend to highlight our strengths, not our weaknesses. Good luck to all. Tokyo